Concepedia

Kevin DeMent

KD

Statistics

Publications

10

Citations

357

H-Index

10

Active since

2015

Affiliations

Gene Therapy Laboratory(Current)

NewLink Genetics (United States)

WuXi AppTec (China)

Kevin DeMent is an author at Gene Therapy Laboratory specializing in pharmacology, pharmacy, and drug discovery.

Publications per year

2015–2022

10

Publications

10

Use of Physiologically Based Pharmacokinetic (PBPK) Modeling for Predicting Drug-Food Interactions: an Industry Perspective

Arian Emami Riedmaier, Kevin DeMent, James E. Huckle et al. · The AAPS Journal · 2020 · 96 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Nonselective inhibition of the epigenetic transcriptional regulator BET induces marked lymphoid and hematopoietic toxicity in mice

Dong U. Lee, Paula Katavolos, Gopinath S. Palanisamy et al. · Toxicology and Applied Pharmacology · 2016 · 46 citations · Full text

Life Sciences, Immunology, Molecular Biology +13

Aminoisoxazoles as Potent Inhibitors of Tryptophan 2,3-Dioxygenase 2 (TDO2)

Zhonghua Pei, Rohan Mendonca, Lewis Gazzard et al. · ACS Medicinal Chemistry Letters · 2018 · 40 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +13

Development of Potent and Selective Pyrazolopyrimidine IRAK4 Inhibitors

Marian C. Bryan, Joy Drobnick, Alberto Gobbi et al. · Journal of Medicinal Chemistry · 2019 · 30 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Improved anti-tumor immunity and efficacy upon combination of the IDO1 inhibitor GDC-0919 with anti-PD-l1 blockade versus anti-PD-l1 alone in preclinical tumor models

Jessica Spahn, Jing Peng, Edward Lorenzana et al. · Journal for ImmunoTherapy of Cancer · 2015 · 28 citations · Full text

Life Sciences, Immunology, Pharmacology +13

1–5 of 10